An observational study in Persistent Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Active, not recruiting at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.
Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 13th largest by enrollment of the 18 observational ones that give a count, is one of 5 that started in 2021, is one of 18 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 70th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic Cardiac Ablation Solutions · Sites in United States, Australia, Belgium and 3 more countries
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in United States, Canada, Korea, Republic of
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Australia, Belgium, Canada and 13 more countries
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Czechia
Ages 18–75
Medtronic Cardiac Ablation Solutions · Sites in Lithuania
Ages 18–75
By country, each count listing its studies:
Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 4 · Phase 4 15
First in 2000; this study’s year is marked. 5 started in 2021.
This study's enrollment of 393 is above the median of 300 across 1,404 observational studies indexed under Atrial Fibrillation.
Median enrollment 155 across the 66 interventional studies, 777 across the 18 observational. Of the 70 that completed or were terminated, 39 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Ablation Solutions, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Ablation Solutions is the lead sponsor of 37 studies on the registry; 9 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.
3 of the studies in Atrial Fibrillation by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT06578104Medtronic Cardiac Ablation SolutionsPULSED AF Post-Approval Study | 2027-04-30 |
| NCT07308847Medtronic Cardiac Ablation SolutionsHorizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Atrial Fibrillation by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
The STOP Persistent AF Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The PAS is a prospective, global, multicenter, observational trial. The purpose of the PAS is to describe long-term clinical performance and safety data in the Persistent AF population treated with Arctic Front™ and Freezor™ MAX Families of Cardiac Cryoablation Catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System). This PAS is a condition of the Pre-Market Approval order (P100010/S098) by the U.S. Food and Drug Administration. Up to 400 subjects will be enrolled to ensure 355 are treated. A minimum of 50% of patients will be enrolled and treated in the US. The follow-up duration for this post-approval study will be 36-months.
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ Cardiac Cryoablation Catheter System may be approached regarding enrollment in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
Estimate the 36-month freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ Cardiac Cryoablation Catheter System.
Time frame: 36 months
Freedom from Primary Safety Events
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ Cardiac Cryoablation Catheter System through 12-months.
Time frame: 12 months
Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.
Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 64 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2028 → Dec 2026 and completion Jul 2028 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiac Ablation Solutions →